BDBM538658 NCGC 00249373::US11254667, Compound I-17::US11542261, Compound I-17
SMILES Clc1ccc2ncc(-c3cccc(NC4CCCNC4)n3)n2c1
InChI Key InChIKey=SZFYZDIPRMLBDC-UHFFFAOYSA-N
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 27 hits for monomerid = 538658
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children''S Hospital Medical Center
US Patent
Children''S Hospital Medical Center
US Patent
Affinity DataIC50: 22nMAssay Description:AlphaScreen SureFire STAT5 (pTyr694;Tyr699) Assay kit (Perkin Elmer). Assay was performed according to manufacturer protocol.More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 22nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children''S Hospital Medical Center
US Patent
Children''S Hospital Medical Center
US Patent
Affinity DataKd: 0.610nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835H](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.640nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835V](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0930nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.400nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.310nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [D835V](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.0360nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3 [F691L](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 0.410nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children''S Hospital Medical Center
US Patent
Children''S Hospital Medical Center
US Patent
Affinity DataKd: 5nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [N841I](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 1.20nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [R834Q](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 3.40nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [564-710,762-958](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 11nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 1(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 150nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataKd: 3.40nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 40.7nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetCyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 588nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children''S Hospital Medical Center
US Patent
Children''S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 1(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 1.48E+3nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 11.2nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 167nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetPlatelet-derived growth factor receptor beta(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 67nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 10.5nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Affinity DataIC50: 7.67E+3nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center
US Patent
Children'S Hospital Medical Center
US Patent
Affinity DataIC50: 22nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair